Omada Health President Shao Wei-Li sold 4,036 shares across two transactions priced between $21.78 and $22.53 per share. The transaction matters to investors because Wei-Li retained 295,313 Omada Health shares afterward, leaving a disclosed ownership position following the sale.
Key Highlights
- Both transactions were reported with SEC transaction code S.
- The disclosed prices ranged from $21.78 to $22.53 per share.
- Shao Wei-Li owned 295,313 shares after the transactions.
Omada Health, Inc. (NASDAQ: OMDA) President Shao Wei-Li sold 4,036 shares. The transactions involved Omada Health shares.
Two Sales Covered September 10
The transactions took place on 10 September 2026 and were completed in two separate transactions. Prices ranged from $21.78 to $22.53 per share. Both transactions were reported with SEC transaction code S. Shao Wei-Li is Omada Health’s president. The reported sale involved 4,036 shares in total. The ownership figure reflects Shao Wei-Li’s position after both sales. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many Omada Health shares did Shao Wei-Li sell?
A: Shao Wei-Li sold 4,036 Omada Health shares across two transactions. The reported trades were completed on 10 September 2026. The filing identifies both transactions as sales under SEC transaction code S.
Q: What prices did Omada Health President Shao Wei-Li receive?
A: The filing reports prices ranging from $21.78 to $22.53 per share for the Omada Health share sales. Both transactions were reported with SEC transaction code S.
Q: How many Omada Health shares did Shao Wei-Li retain?
A: Shao Wei-Li owned 295,313 Omada Health shares after the transactions. This ownership figure reflects the position reported following both sales.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.